These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Mar 7, 2016
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced that it will be presenting at the 2016 Barclays Global...
- Feb 25, 2016
Pfenex Inc. (NYSE MKT: PFNX) announced today that its fourth quarter and full year 2015 financial results will be released on Thursday, March 10, 2016, after the close of market. At 4:30 pm...
- Dec 16, 2015
Pfenex Inc. (NYSE MKT: PFNX) announced today the pricing of its secondary offering of 600,000 shares of its common stock at a price to the public of $11.75 per share. All of such shares will be...
- Dec 15, 2015
Pfenex Inc. (NYSE MKT: PFNX) announced today the launch of a proposed secondary public offering of 600,000 shares of its common stock. All of such shares will be offered and sold by The Dow...
- Nov 13, 2015
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
- Oct 27, 2015Pfenex To Report Third Quarter 2015 Results and Provide Business Update on Friday, November 13, 2015
Pfenex Inc. (NYSE MKT: PFNX) announced today that its third quarter 2015 financial results will be released on Friday, November 13, 2015, before the open of market. At 8:30 am Eastern Time, Pfenex...
- Sep 15, 2015
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biosimilars company, announced today that Dennis M. Fenton, Ph.D., has been appointed to the company's board of directors, deepening the...
- Sep 11, 2015
Pfenex Inc. (NYSE MKT: PFNX) announced today that Bertrand C. Liang, chief executive officer of Pfenex will be presenting at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt New...
- Aug 17, 2015Contract administered by the Biomedical Advanced Research and Development Authority focused on Pfenex's Px563L
Pfenex Inc. (NYSE MKT: PFNX), announced today it has signed a five year, cost plus fixed fee contract valued at up to $143.5 million with the Biomedical Advanced Research and Development Authority...
- Aug 13, 2015
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
